Notice of the Establishment of a Joint Company for Generic Drugs between TOHO HOLDINGS CO., LTD. and SUZUKEN CO., LTD.

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Chairman of the Board and Representative Director, Chief Executive Officer (CEO): Norio Hamada, hereinafter, “TOHO HOLDINGS”) and SUZUKEN CO., LTD. (Headquarters: Nagoya, Aichi Prefecture; President and CEO: Hiromi Miyata; hereinafter “SUZUKEN”) are pleased to announce the establishment of a joint company for generic drugs, “TS Pharma Co., Ltd.,” effective April 1, 2019, as announced on February 18, 2019.

1. The objectives of the joint company
Through planning and negotiations on generic drugs, the newly established joint company aims to ensure a stable supply of safe, low-cost and high-quality generic drugs, which reflects the opinions of its clients, and also takes patients’ viewpoints into account.

KYOSOMIRAI PHARMA CO., LTD., a subsidiary of TOHO HOLDINGS and SANWA KAGAKUKENKYUSHO CO., LTD., a subsidiary of SUZUKEN, will deploy sales of generic drugs.

In addition to the deployment of new distribution models for generic drugs, it will work together with pharmaceutical manufacturers to discuss the development of a joint manufacturing system, joint procurement of materials such as active pharmaceutical ingredients and packaging materials, and supply chain efficiency including manufacturers' logistics.

2. Summary of the joint company
1) Company name: TS Pharma Co., Ltd.
2) Corporate representative: Representative Director: Atsushi Udoh (Executive Managing Director, TOHO HOLDINGS / Vice President and Representative Director, Toho Pharmaceutical Co., Ltd. / Representative director and president, KYOSOMIRAI PHARMA CO., LTD.)
Representative Director: Shigeru Asano (Executive Vice President, Senior General Manager of Corporate Management Headquarters, General Manager of Corporate Planning Department, In charge of Risk Management and Pharmaceutical Affairs, SUZUKEN)
3) Location: PMO Akihabara 6F, 3-11-6, Iwamotocho, Chiyoda-ku, Tokyo
4) Establishment: April 1, 2019
5) Business contents: Conduct the planning and the negotiations on generic drugs, etc.
6) Capital: 10 million yen
7) Fiscal year end: March 31
8) Shareholder composition: TOHO HOLDINGS 50%, SUZUKEN 50%

Please be advised that this is a joint press release by TOHO HOLDINGS and SUZUKEN.

Contact: Makoto Kawamura / Public and Investor Relations Department, TOHO HOLDINGS CO., LTD
Office: GranTokyo South Tower 13F, 1-9-2 Marunouchi, Chiyoda-ku, Tokyo 100-6613, Japan
TEL: 81-3-6838-2803

Hirohiko Hayashi / Corporate communication, SUZUKEN CO., LTD.
8 Higashi Kataha-machi, Higashi-ku, Nagoya, Aichi 461-8701, Japan
TEL: 81-52-950-6307